Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00545454 | Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis | PHASE2 | COMPLETED | 79 | — | — | Oct 1, 2007 | Jun 1, 2008 | Aug 8, 2017 | 7 | Bulgaria, Croatia +5 |
| Arm | Type | Description |
|---|---|---|
| SSR150106 QD | EXPERIMENTAL | 90 micro grams oral solution once daily (QD) |
| SSR150106 OEQD | EXPERIMENTAL | 90 micro grams oral solution once every other day (OEQD) |
| Placebo | PLACEBO_COMPARATOR | oral solution QD or OEQD |
| Name | Type | Description |
|---|---|---|
| SSR150106 | DRUG | - |
| Placebos | DRUG | - |
Inclusion Criteria: * Either treatment-naïve patients, or those who have discontinued their Rheumatoid Arthritis-directed medication due to intolerability or insufficient efficacy * At least 9 out of 68 tender joints; 6 out of 66 swollen joints; morning stiffness 45 min * C-Reactive Protein \>=1.8 ...